Shanghai Haixin Group Co., Ltd. Class A

Shanghai Haixin Group Co., Ltd. Class A

0.25
USD
0.00
(0.00%)
0.01EPS
21.33P/E
1.52BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.21
0.18
0.17
0.17
0.16
0.18
0.18
0.15
0.25
0.24
0.19
0.13
0.12
0.26
Basic EPS, GAAP
0.01
0.05
0.03
0.01
0.02
0.02
0.02
0.02
0.02
0.03
0.03
0.02
0.03
0.08
Free Cash Flow per Basic Share
-0.01
- -
-0.03
-0.01
-0.01
-0.01
-0.04
-0.01
0.02
0.01
-0.02
0.01
- -
- -
Dividend per Share
- -
0.01
0.02
0.02
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.03
Book Value per Share
0.49
0.88
0.75
0.68
0.62
0.56
0.63
0.69
0.68
0.63
0.65
0.71
0.78
0.79
Tangible Book Value per Share
0.48
0.86
0.74
0.67
0.61
0.55
0.62
0.67
0.68
0.63
0.65
0.71
0.78
0.79
Basic Weighted Avg Shares
6,065
6,069
6,069
6,071
6,070
6,071
6,069
6,069
6,070
6,068
6,066
6,070
6,068
2,421
Sales/Revenue/Turnover
1,262
1,110
1,052
1,012
1,000
1,099
1,112
933
1,511
1,440
1,183
796
758
641
Operating Margin (%)
-6.09
-5.49
-3.04
-6.36
-5.21
3.42
-3.66
-2.5
2.27
1.7
5.26
3.9
5.97
7.76
Depreciation Expense
42
38
31
33
30
27
27
27
27
25
24
21
19
- -
Net Income, GAAP
65
291
157
90
105
135
104
119
132
164
166
151
176
191
Effective Tax Rate (%)
20.76
25.95
5.71
26.6
24.71
13.35
18.77
6.88
9.67
13.87
7.28
5.83
5.04
5.02
Profit Margin (%)
5.18
26.21
14.97
8.89
10.53
12.31
9.35
12.8
8.74
11.39
14.04
18.97
23.23
29.79
Working Capital
234
616
604
546
492
445
410
336
432
615
663
686
1,023
1,100
LT Debt
- -
- -
5
17
32
41
106
142
1
12
12
- -
77
102
Total Equity
3,216
5,540
4,803
4,339
3,950
3,623
4,048
4,379
4,283
4,019
4,135
4,501
4,917
4,984
Return on Invested Capital (%)
1.76
6.37
1.97
0.93
2.19
4.07
2.9
2.29
2.29
4.78
4.8
3.93
4.12
4.23
Return on Capital (%)
2.52
6.81
2.84
3
2.98
3.04
2.64
3.3
3.96
3.17
3.46
3.09
3.33
3.6
Return on Common Equity (%)
2.23
6.99
3.18
2.06
2.66
3.76
2.86
2.97
3.18
4.12
4.25
3.64
3.89
4.15

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
13
13
13
LT Borrowings
102
102
102
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
6,068
6,068
6,068
Market Capitalization
11,342
10,868
10,210

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,296
1,335
1,370
Cash, Cash Equivalents & STI
1,088
1,128
1,114
Accounts Receivable, Net
63
56
101
Inventories
59
68
60
Total Current Liabilities
231
283
269
Payables & Accruals
- -
- -
- -
ST Debt
13
13
13
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
0.56%
2.52%
9.23%
Free Cash Flow
-87.7%
-225.5%
-98.77%
Net Income, GAAP
3.79%
8.71%
16.6%
Sales/Revenue/Turnover
-0.81%
0.38%
-4.82%
Total Cash Common Dividend
-1.93%
8.42%
-38.33%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
209
198
199
190
796
2025
202
170
- -
160
758
2026
150
162
169
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.06
0.03
0.01
0.02
2025
0.01
0.06
- -
0.03
0.03
2026
- -
0.08
0.02
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.01
0.07
-0.01
0.01
2025
- -
0.01
- -
-0.01
0.01
2026
- -
0.01
0.05
- -
- -

Company Description

CEO
Xiaowei Ren
Full Time Employees
675
Sector
Process industries
Industry
Textiles
Address
Huaxin Haixin Building Shanghai SH China 200001
IPO Date
Apr 4, 1994
Website
haixin.com
Business
Shanghai Haixin Group Co., Ltd. Shanghai Haixin Group Co., Ltd. operates as a China-based diversified investment holding group primarily engaged in pharmaceuticals, textiles and clothing, financial investments, industrial real estate leasing and management, and commodity trading. The company manufactures and sells pharmaceutical products including those focused on tumor treatment and biomedicine; produces plush fabrics, apparel fabrics, yarns, plush toys, and stuffed toys; leases and manages industrial parks and properties; conducts financial investments through stakes in securities firms and fund management companies such as Changjiang Securities and Changxin Fund Management Co., Ltd.; and trades commodities. Founded in 1986 and headquartered in Shanghai, China, it lists A shares on the Shanghai Stock Exchange since April 1994 and B shares since December 1993, with operations centered in China and international pharmaceutical sales. In recent years, the company pursues a strategic shift outlined in its 2017 five-year development plan emphasizing medical and health as the core business supplemented by real estate and finance, including expansions into medical parks, international medical centers, tumor treatment industries via mergers, acquisitions, joint ventures, and a "platform + medical + capital" model; it reported third-quarter results in 2025 involving partnerships like Hunan Ningrui Investment and implemented 2024 dividend distributions in July 2025.